Rosetta Genomics Signs Marketing Agreement With PACE Claims Services for miRview meso

Rosetta Genomics ROSG announces the signing of an exclusive marketing agreement with PACE Claims Services LLC to provide educational and marketing services on behalf of Rosetta Genomics' miRview meso diagnostic test to defendants and insurers in mesothelioma legal cases worldwide. PACE is a wholly-owned subsidiary of Navigant Consulting, Inc. NCI and is the market leader in asbestos claims administration. In a study published in The Journal of Molecular Diagnostics in September 2010, miRview® meso was shown to be a highly sensitive test for differentiating mesothelioma from carcinomas in the lung or pleura, with a sensitivity of 100% and a specificity of 94%. Through the partnership, PACE will market miRview meso as a key tool in better diagnosing varying forms of cancer, thereby potentially saving defendants who might otherwise pay millions to claimants who were misdiagnosed with mesothelioma. Among the ways PACE will share details of the product are targeted client outreach via email, phone, conferences and in-person meetings; as well as leveraging other strategies that target mesothelioma litigation defendants.